<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02642172</url>
  </required_header>
  <id_info>
    <org_study_id>PN-837-CTIL</org_study_id>
    <nct_id>NCT02642172</nct_id>
  </id_info>
  <brief_title>Prebiotics in Patients With Non-alcoholic Liver Disease</brief_title>
  <official_title>A Randomized, Double - Blind Study With Two Parallel Arms for 4 Months (20 Weeks), Evaluating the Effectiveness of the Prebiotics in Patients With Non-alcoholic Liver Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaplan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaplan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this present study is to evaluating whether prebiotics - ITF (Inulin/OFS
      75/25) is effective in treating patients with non-alcoholic liver disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 60 patients with Non-alcoholic fatty liver disease (NAFLD) which will
      randomize to two groups, receiving either ITF (Inulin/oligofructose-OFS 75/25) or
      maltodextrin (placebo).

      The trial will last for 20 weeks: Stage 1-Run-in period: Subjects will be followed to
      ascertain weight maintenance. Stage 2- Randomized intervention period: Subjects will be
      assigned to receive 16 gram/day of ITF or maltodextrin. Both ITF and placebo will be provided
      in identical opaque packages and both subjects and researchers will be blinded to the
      content. Stage 3- Extension period: All patients will receive 16 gram/day of ITF for 8 weeks.

      After signing informed consent, the following data will be collected: demographics, lifestyle
      habits including dietary questionnaires, and medical history. At the end of week 2, week 12
      and week 20 all the following tests will be performed: Vital Signs: blood pressure,
      anthropometric measurements, body composition determined by bioelectrical impedance analysis
      (BIA). Biochemical blood tests: liver function tests fasting glucose insulin &amp; lipid profile,
      75 gram oral glucose tolerance test (OGTT), CRP (an inflammation marker), SCFA, BCAA, and LBP
      and FGF 19. Fecal samples: fecal samples will be used for microbiota composition analysis,
      and BA analysis. Assessment of liver status At week 2, 12, and 20 by using magnetic resonance
      spectroscopy (1H-MRS), SteatoTest and NashTest (FibroMax™) and by liver enzymes for
      evaluating steohepatitis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the severity of NAFLD determined by liver fat fraction measured by magnetic resonance spectroscopy (1H-MRS)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in the severity of NAFLD determined by inflammation score using SteatoTest and NashTest (FibroMax™)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in the severity of NAFLD determined by liver enzymes</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of gut microbiota composition.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycemic control determine by OGTT.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin sensitivity determine by homeostasis model assessment (HOMA).</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lipid profile (LDL-C, HDL-C, Triglyceride).</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>ITF (Inulin/OFS 75/25)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 gram/day of ITF (Inulin/OFS 75/25)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>16 gram/day of maltodextrin (placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ITF (Inulin/OFS 75/25)</intervention_name>
    <description>Participants will consume 16 g/day ITF</description>
    <arm_group_label>ITF (Inulin/OFS 75/25)</arm_group_label>
    <other_name>Prebiotics- Inulin, OFS - oligofructose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will consume 16 g/day maltodextrin</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>maltodextrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of NAFLD based on fatty infiltration detection by ultrasonography and
             alanine aminotransferase levels of (ALT) ≥ 30 U/L male ≥ 19 U/L females.

          -  Over-weight (BMI ≥ 27 kg/m2) who fulfill the criteria of the National Cholesterol
             Education Program (NCEP) metabolic syndrome

          -  Willing to sign informed consent to participate in the study

          -  Patients without diabetes or with well-controlled diabetes (HbA1C &lt; 7.5%) who are
             treated by diet ± metformin

        Exclusion Criteria:

          -  Pregnancy

          -  Uncontrolled diabetes

          -  Diabetic treatment other than metformin, unusual diets (vegetarian, vegan), usage of
             antibiotics, probiotics or prebiotics up to 6 months prior to study, alcohol abuse,
             presence of gastrointestinal or mental disorders, weight-loss treatment, bariatric
             surgery

          -  Serious medical conditions

          -  Evidence of another etiology for chronic liver disease such as: hepatitis B, hepatitis
             C, HIV, autoimmune diseases and metabolic diseases, medications with known
             hepatotoxicity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaakov Maor, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaplan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yaakov Maor, Dr</last_name>
    <phone>972-542060260</phone>
    <email>yaakovma1@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naama Reshef, M.sc Nutr</last_name>
    <phone>972506705552</phone>
    <email>reshefn2@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rechovot</city>
        <zip>81207</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naama reshef</last_name>
      <phone>+972506705552</phone>
      <email>reshefn2@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, Bindels LB, de Vos WM, Gibson GR, Thissen JP, Delzenne NM. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut. 2013 Aug;62(8):1112-21. doi: 10.1136/gutjnl-2012-303304. Epub 2012 Nov 7.</citation>
    <PMID>23135760</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>October 29, 2016</last_update_submitted>
  <last_update_submitted_qc>October 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaplan Medical Center</investigator_affiliation>
    <investigator_full_name>Yaakov Maor</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Inulin, OFS (oligofructose)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

